TACE Combined With Penpulimab and Anlotinib for Advanced HCC

Clinical trial NCT05344924 · UNKNOWN

Trial details

NCT number: NCT05344924
Sponsor: Zhongda Hospital
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2022-10-12
Primary completion: 2023-03-31
Enrollment: 109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.